Nurix Therapeutics, Inc.
NRIX
$15.96
-$0.32-1.97%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -295.28M | -264.46M | -244.79M | -207.32M | -208.40M |
| Total Depreciation and Amortization | 17.90M | 18.26M | 17.23M | 16.37M | 15.37M |
| Total Amortization of Deferred Charges | 600.00K | 600.00K | 1.30M | 1.30M | 1.30M |
| Total Other Non-Cash Items | 30.15M | 27.73M | 25.47M | 23.23M | 22.23M |
| Change in Net Operating Assets | -13.67M | -31.60M | -29.60M | -48.76M | -22.22M |
| Cash from Operations | -260.29M | -249.47M | -230.38M | -215.18M | -191.72M |
| Capital Expenditure | -11.56M | -14.00M | -10.98M | -10.61M | -9.87M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.06M | 161.86M | 17.67M | -54.51M | -257.82M |
| Cash from Investing | -1.51M | 147.85M | 6.69M | -65.12M | -267.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 257.14M | 238.64M | 203.16M | 247.77M | 485.53M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | -15.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 257.14M | 238.64M | 203.16M | 247.77M | 485.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.65M | 137.03M | -20.54M | -32.53M | 26.10M |